Skip to search formSkip to main contentSkip to account menu

vibegron

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Treatment of Non-neurogenic Lower Urinary Tract Symptoms-A Review of Key Publications from 2018 Onward.
2020
2020
Effects of a new β3‐adrenoceptor agonist, vibegron, on neurogenic bladder dysfunction and remodeling in mice with spinal cord injury
To examine vibegron effects on lower urinary tract dysfunction (LUTD) in mice with spinal cord injury (SCI). 
2020
2020
Additive effects of intravenous and intravesical application of vibegron, a β3-adrenoceptor agonist, on bladder function in rats with bladder overactivity
To examine the effects of intravenous and intravesical application of vibegron, a new β3-adrenoceptor (β3-AR) agonist, on bladder… 
2019
2019
PD14-01 ONCE-DAILY VIBEGRON, A NOVEL ORAL &bgr;3 AGONIST DOES NOT INHIBIT CYP2D6, A COMMON PATHWAY FOR DRUG METABOLISM IN PATIENTS ON OAB MEDICATIONS
INTRODUCTION AND OBJECTIVES: Vibegron is a selective &bgr;3-adrenergic receptor agonist in development for overactive bladder… 
Review
2019
Review
2019
LBA-02 INTERNATIONAL PHASE 3, DOUBLE-BLIND, PLACEBO- AND ACTIVE (TOLTERODINE)-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VIBEGRON IN PATIENTS WITH SYMPTOMS OF OVERACTIVE BLADDER: EMPOWUR
INTRODUCTION AND OBJECTIVES: Vibegron is a novel, once-daily, oral &bgr;3-adrenoceptor (AR) agonist in development for treatment… 
2019
2019
Effects of the combination of vibegron and imidafenacin on bladder function in urethane-anesthetized rats.
2019
2019
Editorial Comment to Efficacy of novel β3‐adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post‐hoc analysis of a randomized, double‐blind, placebo‐controlled phase…
Kyorin, Astellas and Taiho; grants from Kissei, Astellas, Daiichi-Sankyo, Nippon Shinyaku, Taiho and Takeda; and speaker fees… 
2018
2018
Future Considerations in Overactive Bladder Pharmacotherapy
  • K. Andersson
  • Contemporary Pharmacotherapy of Overactive…
  • 2018
  • Corpus ID: 81236399
New alternatives for treatment of overactive bladder (OAB) syndrome are continuously being explored. Despite ongoing nonclinical… 
2018
2018
Editorial Comment from Dr Chapple to Long‐term safety and efficacy of the novel β3‐adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study
This interesting manuscript by Yoshida et al. represents the long-term data on safety and efficacy of a new beta 3 agonist… 
2018
2018
Editorial Comment from Dr Yamanishi to Long‐term safety and efficacy of the novel β3‐adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study
For the treatment of overactive bladder, anti-muscarinic (Anti-M) drugs have been the treatment of choice. There are more than 10… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)